Asset profile
retatrutide
Peptide
Evidence outlook · lead readout
TRIUMPH-2 (NCT05929079) · Type 2 Diabetes, Obesity, Overweight, Obstructive Sleep Apnea
The completed lead evidence has the design features that historically survive confirmatory trials: randomized, controlled, and adequately powered against a prespecified clinically accepted endpoint.
TRIUMPH-2 (NCT05929079): This was a randomized, double-blind, placebo-controlled trial with 1,152 participants. The sponsor reports large, dose-related weight reductions with retatrutide (up to 20.8%) compared with placebo (4.0%) at week 80, describing the trial as successful.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Also in development:Chronic Kidney Disease · Phase 3Atherosclerotic Cardiovascular Disease · Phase 3Type 2 Diabetes · Phase 3
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
224 competitors in this universe: 5 direct rivals (same mechanism and indication), 0 same-class, 219 same-indication; 72 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Retatrutide: this drug | Phase 3 | Peptide | GLP-1/GIP/glucagon receptor (triple) | ||
| UBT251 | Phase 3 | Peptide | GLP-1/GIP/glucagon receptor (triple) | ||
| HM15211 | Phase 2 | Peptide | GLP-1/GIP/glucagon receptor (triple) | ||
| HM15275 | Phase 2 | Peptide | GLP-1/GIP/glucagon receptor (triple) | ||
| HRS-4729 | Phase 2 | Peptide | GLP-1/GIP/glucagon receptor (triple) | ||
| NNC0662-0419 | Phase 2 | Peptide | GLP-1/GIP/glucagon receptor (triple) | ||
| Afrezza | Approved | Peptide | Insulin receptor (basal), Insulin | ||
| Alirocumab (Praluent) | Approved | Monoclonal antibody | PCSK9 | ||
| Alogliptin (Nesina) | Approved | Small molecule | DPP-4 | ||
| Atrasentan (Vanrafia) | Approved | Small molecule | Endothelin A receptor | ||
| Avacopan (Tavneos) | Approved | Small molecule | Complement C5a receptor 1 (C5aR1/CD88) | ||
| Baxdrostat (Baxfendy) | Approved | Small molecule | Aldosterone synthase (CYP11B2) | ||
| Bempedoic Acid (Nexletol) | Approved | Small molecule | Adenosine Triphosphate-Citrate Lyase Inhibitor, ATP citrate lyase | ||
| Bempedoic Acid / Ezetimibe | Approved | Small molecule | ATP citrate lyase (ACLY, bempedoic acid) and NPC1L1 (ezetimibe) | ||
| Bexagliflozin (Brenzavvy) | Approved | Small molecule | SGLT2 | ||
| Budesonide (targeted-Release) (TARPEYO / Nefecon) | Approved | Small molecule | Glucocorticoid receptor |
…and 209 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(9 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (2)
2027 (3)
March 2027 (1)
July 2027 (1)
What to watch
September 2027 (1)
What to watch
2028 (2)
2029 (1)
February 2029 (1)
What to watch
2030 (1)
August 2030 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.